Q4 2025 Castle Biosciences Inc Earnings Call Transcript

Feb 26, 2026 / 09:30 PM GMT

Release Date Price: $31.88 (+3.41%)

Transcript 10-K8-K

Key Points

Positve

Castle Biosciences Inc (CSTL) reported strong revenue growth with a total of $344.2 million for 2025, driven by core revenue drivers and a 37% increase in test report volume.
The company achieved significant growth in its Tissue Cipher test, with an 86% increase in test reports compared to 2024, highlighting its clinical value.
Castle Biosciences Inc (CSTL) successfully launched its Advanced ADTX test, expanding its market reach and showing promising early adoption among dermatological accounts.
The company maintained a strong balance sheet with cash equivalents and marketable securities totaling $299.5 million as of December 31, 2025.
Castle Biosciences Inc (CSTL) continues to invest in growth initiatives, including strategic acquisitions and collaborations, positioning itself for sustained long-term growth.

Negative

The company reported a net loss of $24.2 million for the full year 2025, compared to a net income of $18.2 million in 2024.
Gross margin for 2025 decreased to 69.2% from 78.5% in 2024, impacted by the loss of revenue from certain tests and amortization expenses.
Castle Biosciences Inc (CSTL) anticipates immaterial revenue contribution from its Advanced ADTX test in 2026, with material contributions expected in 2027 or 2028.
The company faces challenges in achieving FDA approval for its Decision DX melanoma test, which could impact clinician adoption and reimbursement.
Operating expenses increased in 2025, driven by higher personnel costs and expanded headcount, which may continue to rise as the company invests in growth initiatives.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CSTL.OQ - Castle Biosciences Inc
Q4 2025 Castle Biosciences Inc Earnings Call
Feb 26, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Castle Bioscience's 4th quarter and full year 2025 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question-and-answer session.

I would like to turn the call over to Camila Sechero, Vice President of Investor Relations and Corporate Affairs.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon, everyone. Welcome to Castle Bioscience's 4th quarter and full year 2025 results conference call. Joining me today are

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.